Key points 2,500 years ago in Greece, Hippocrates, the Father of Medicine, said, All diseases begin in the gut. GLP-1 agonist meds like Ozempic reduce food, alcohol and cocaine intake and may improve behavioral addictions
Orforglipron doesn't match tirzepatide's 20% weight loss
Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden
These mixed results underscore the importance of setting realistic expectations before starting, providing reassurance and confidence to potential buyers
Early trial data suggest retatrutide could lead to greater average weight loss than tirzepatide, but its long-term safety, side effects, and real-world tolerability are still being studied
Most people notice increasing hunger within two to three weeks of their last injection